Benzene and Acute Myeloid Leukemia: A Clinical Evidence Review
From General Health Awareness to Focused Occupational Concern
The legacy of general health and science information has long provided foundational knowledge about environmental factors and their potential effects on human well-being. Within this broad context, public health discussions have historically emphasized the importance of understanding chemical exposures in everyday life, from household products to industrial materials. This heritage established a framework for recognizing that certain substances, when encountered under specific conditions, may warrant closer scrutiny regarding their long-term implications for health. As this general awareness evolved, attention naturally turned toward more specialized areas of inquiry, particularly those involving occupational settings where exposure levels can be significantly higher and more sustained than in the general environment. The transition from broad health education to focused occupational concern reflects a logical progression in scientific and public health discourse. In workplace environments, the potential for repeated contact with chemical agents becomes a central consideration, shifting the emphasis from general population risks to the specific circumstances of those whose daily activities involve handling or being near such substances. This pivot acknowledges that while general health information serves as an essential starting point, the concentrated nature of occupational exposure demands a more targeted examination of potential health outcomes, setting the stage for detailed investigation into specific chemical agents and their relationship to disease.
Benzene as a Recognized Myelotoxin and Carcinogen
Building on the general framework of occupational health concerns, benzene emerges as a critical agent of interest. Benzene is a well-established myelotoxin and recognized risk factor for the development of acute myeloid leukemia (AML). Chronic exposure to benzene can augment the risk for the onset of AML, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279). Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013). Previous studies have established a causal relationship between occupational benzene exposure and AML (https://pubmed.ncbi.nlm.nih.gov/38727681). The mode of action for AML development following benzene exposure is anticipated to include multiple earlier key events, which can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013).
Clinical Presentation and Diagnosis of Acute Myeloid Leukemia
AML is a hematologic malignancy characterized by the clonal expansion of myeloid blasts in the bone marrow, peripheral blood, or other tissues. Clinical presentation typically includes symptoms related to bone marrow failure, such as fatigue, pallor, infection, and bleeding, as well as signs of extramedullary involvement. Diagnosis is confirmed by morphologic evaluation of bone marrow aspirate and biopsy, immunophenotyping, cytogenetic analysis, and molecular testing. The disease can arise de novo or secondary to prior chemotherapy, radiation, or exposure to myelotoxic agents such as benzene.
Benzene Pharmacology and Reported Adverse Effects
Benzene is a volatile organic compound that is absorbed primarily through inhalation and dermal exposure. It is metabolized in the liver to reactive intermediates, including benzene oxide, phenol, hydroquinone, and benzoquinone, which can cause cellular damage. Benzene is acknowledged as a myelotoxin, and its carcinogenic ability has been reported (https://pubmed.ncbi.nlm.nih.gov/34069279). Chronic exposure to benzene can be one of the risk elements for solid cancers and hematological neoplasms (https://pubmed.ncbi.nlm.nih.gov/34069279). In addition to AML, benzene exposure has been associated with increased risks of all childhood cancers and acute myeloid leukemia in children, with an odds ratio of 1.22 (95% CI: 1.02-1.46) per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753).
Mechanistic Pathways Linking Benzene to Acute Myeloid Leukemia
Possible mechanisms of benzene initiation of hematological tumors have been identified, including a genotoxic effect, an action on oxidative stress and inflammation, and the provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279). However, it is becoming evident that genetic alterations and other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279). Epigenetic effects, such as altered gene expression, have been implicated in benzene-induced hematologic neoplasms (https://pubmed.ncbi.nlm.nih.gov/34069279). The mode of action for AML development leading to mortality is anticipated to include multiple earlier key events, which can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013). Prevention of these early events would lead to prevention of the apical, adverse outcomes, the morbidity and mortality caused by myelodysplastic syndromes and AML (https://pubmed.ncbi.nlm.nih.gov/33429013). Incorporation of key event information should modify the risk model, but few modification approaches have been suggested (https://pubmed.ncbi.nlm.nih.gov/33429013).
Adequacy of Warnings Regarding Benzene and Acute Myeloid Leukemia
The evidence indicates that benzene exposure is a recognized cause of AML, with a causal relationship established in occupational settings (https://pubmed.ncbi.nlm.nih.gov/38727681). Warnings regarding benzene's myelotoxicity and carcinogenicity are generally provided in occupational safety guidelines and material safety data sheets. However, the adequacy of such warnings may vary depending on the context, such as industrial versus consumer product use, and the specificity of warnings regarding AML risk. The evidence does not directly address the completeness or effectiveness of specific warning labels, but the established causal link underscores the importance of clear communication about the risk of AML from benzene exposure.
Causation-Related Considerations for Affected Patients
For patients diagnosed with AML who have a history of benzene exposure, causation considerations include the level and duration of exposure, latency period, and presence of other risk factors. Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013). The exposure-response relation between benzene and AML has been estimated by combining epidemiologic, human biomarker, and animal data, with a linear meta-regression model best predicting AML risks (https://pubmed.ncbi.nlm.nih.gov/34906966). This integrated approach can inform risk assessment for affected individuals.
Timeline Between Exposure and Documented Harm
The timeline between benzene exposure and development of AML can vary, with latency periods typically ranging from several years to decades. The evidence does not provide a specific latency range, but the mode of action includes multiple key events that occur over time, such as hematotoxicity and genetic toxicity in peripheral blood (https://pubmed.ncbi.nlm.nih.gov/33429013). Prevention of these early events would prevent the apical adverse outcomes of morbidity and mortality from AML (https://pubmed.ncbi.nlm.nih.gov/33429013). The Swiss National Cohort study examined occupational benzene exposure and mortality risk of lymphohaematopoietic cancers, linking mortality records to census data, which suggests that long-term follow-up is necessary to document harm (https://pubmed.ncbi.nlm.nih.gov/38727681).
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the established link between benzene and acute myeloid leukemia?
What are the mechanisms by which benzene causes leukemia?
Possible mechanisms include genotoxic effects, oxidative stress and inflammation, and immunosuppression. Epigenetic effects such as altered gene expression have also been implicated. The mode of action involves multiple key events including hematotoxicity and genetic toxicity in peripheral blood (https://pubmed.ncbi.nlm.nih.gov/34069279,https://pubmed.ncbi.nlm.nih.gov/33429013).
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.